Stocks to Buy in 2024: Supernus Pharmaceuticals’s (SUPN) Q4 Earnings Beat Expectations
Supernus Pharmaceuticals beat analysts’ revenue expectations by 16.9% last quarter, reporting revenues of $175.7 million, up 14.2% year on year. The company's impressive performance was driven by strong sales of its flagship product, Tenexa Capsules. Supernus Pharmaceuticals has consistently delivered solid earnings growth, positioning itself for long-term success in the specialty pharmaceuticals sector.
- This quarter's revenue decline may be a sign that Supernus Pharmaceuticals is transitioning into a more stable and predictable business model, which could lead to increased investor confidence.
- How will Supernus Pharmaceuticals's management use its cash reserves to drive future growth, considering its aggressive share buyback program?